Renalytix AI (GB:RENX) has released an update.
Renalytix plc has announced a management change with O. James Sterling stepping down as CFO and Joel R. Jung stepping in as Interim CFO during the transition. The company has achieved significant cost reductions this fiscal year and is aligning its business for commercial adoption with its KidneyIntelX becoming a standard of care for chronic kidney disease. CEO James McCullough acknowledges Sterling’s contributions and looks forward to the company’s new phase focusing on sales and marketing in a large market space.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
